Literature DB >> 21431400

Regression of paclitaxel-induced maculopathy with oral acetazolamide.

Kerstin Maria Meyer, Thomas Klink, Selma Ugurel, Eva-Bettina Bröcker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21431400     DOI： 10.1007/s00417-011-1642-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  5 in total

1.  Cystoid macular edema secondary to nab-paclitaxel therapy.

Authors:  Conleth G Murphy; Joseph B Walsh; Clifford A Hudis; Diana Lake; Maria Theodoulou
Journal:  J Clin Oncol       Date:  2010-08-30       Impact factor: 44.544

2.  Paclitaxel maculopathy.

Authors:  Mandar M Joshi; Bruce R Garretson
Journal:  Arch Ophthalmol       Date:  2007-05

3.  Ophthalmic toxicity following paclitaxel infusion.

Authors:  L S Hofstra; E G de Vries; P H Willemse
Journal:  Ann Oncol       Date:  1997-10       Impact factor: 32.976

4.  [A case of cystic maculopathy during paclitaxel therapy].

Authors:  Sei Ito; Masatoshi Okuda
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2010-01

5.  Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Authors:  Axel Hauschild; Sanjiv S Agarwala; Uwe Trefzer; David Hogg; Caroline Robert; Peter Hersey; Alexander Eggermont; Stephan Grabbe; Rene Gonzalez; Jens Gille; Christian Peschel; Dirk Schadendorf; Claus Garbe; Steven O'Day; Adil Daud; J Michael White; Chenghua Xia; Kiran Patel; John M Kirkwood; Ulrich Keilholz
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544
  5 in total
  8 in total

1.  Topical dorzolamide therapy for taxane-related macular oedema.

Authors:  J P Ehlers; H Rayess; N Steinle
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

Review 2.  Cystoid macular oedema without leakage in fluorescein angiography: a literature review.

Authors:  Masood Naseripour; Sara Hemmati; Samira Chaibakhsh; Arzhang Gordiz; Leila Miri; Fatemeh Abdi
Journal:  Eye (Lond)       Date:  2022-09-10       Impact factor: 4.456

3.  Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema.

Authors:  Mark M Hassall; Nicholas Howard Andrew
Journal:  BMJ Case Rep       Date:  2016-04-19

Review 4.  Drug-induced macular edema.

Authors:  Olga E Makri; Ilias Georgalas; Constantine D Georgakopoulos
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

5.  Dorzolamide chlorhydrate versus acetazolamide in the management of chronic macular edema in patients with retinitis pigmentosa: description of three case reports.

Authors:  Elena Pacella; Loredana Arrico; Valentina Santamaria; Paolo Turchetti; Maria Rosaria Carbotti; Giuseppe La Torre; Fernanda Pacella
Journal:  Ophthalmol Eye Dis       Date:  2014-05-27

6.  Dexamethasone intravitreal implant in cystoid macular edema secondary to paclitaxel therapy.

Authors:  Barbara Burgos-Blasco; Samuel Hernandez-Ruiz; Lorenzo Lopez-Guajardo; Juan Donate-Lopez
Journal:  Am J Ophthalmol Case Rep       Date:  2020-03-07

7.  Regression of taxane-related cystoid macular edema after topical dorzolamide treatment: two case reports.

Authors:  Mitsuru Otsubo; Reiko Kinouchi; Takayuki Kamiya; Akitoshi Yoshida
Journal:  J Med Case Rep       Date:  2021-07-21

8.  Paclitaxel may be a risk factor for retinal phototoxicity.

Authors:  Jonathan Malcolm; Caroline Oi Lune Wong; Jared Ching; Shohista Saidkasimova
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.